Pliant Therapeutics Discontinues BEACON-IPF Development
Pliant Therapeutics, Inc. (NASDAQ: PLRX) has recently made a significant announcement regarding its BEACON-IPF clinical trial. Following a thorough review of the data from this Phase 2b/3 clinical trial, the company has decided to discontinue the development of bexotegrast for treating idiopathic pulmonary fibrosis (IPF). This announcement was made after a recommendation from the independent Data Safety Monitoring Board (DSMB) highlighted concerns about the safety profile associated with the treatment.
Details on BEACON-IPF Trial
The BEACON-IPF trial was a global, randomized, double-blind, placebo-controlled study that aimed to evaluate the effectiveness and safety of bexotegrast in patients dealing with IPF. Earlier this year, Pliant announced the voluntary discontinuation of the trial following recommendations from both the DSMB and an external expert panel, triggered by notable adverse events related to IPF.
An in-depth analysis of the trial data revealed that bexotegrast, especially at doses of 160 mg and 320 mg, posed a concerning risk-benefit ratio. Participants receiving this medication experienced a higher likelihood of adverse events, which included disease progression and acute exacerbation of IPF, leading to increased hospitalization and mortality rates. Remarkably, the average time to disease progression in these patients was recorded at 33 weeks, indicating that significant risks may not manifest during shorter treatment courses, as previously seen in the past INTEGRIS-IPF trial.
Trial Results and Conclusions
In terms of pulmonary function, the 12-week results indicated potential improvements in forced vital capacity (FVC) decline among the treatment groups, with reductions of 72 mL for the 160 mg group and 46 mL for the 320 mg group when compared to placebo. However, the outcomes at Week 24 reflected minimal differences, with a mere 58 mL decline in the 160 mg group and 8 mL in the 320 mg group.
These findings have delineated a clear path toward prioritizing patient safety, as emphasized by Dr. Bernard Coulie, President and CEO of Pliant Therapeutics. He expressed deep gratitude towards all those involved in the BEACON-IPF program, acknowledging the significant contributions of patients, caregivers, and research teams.
Oncology Programs Continue to Advance
While the discontinuation of bexotegrast is disappointing, Pliant remains focused on its oncology programs. Currently, they are advancing PLN-101095, a small molecule dual-selective inhibitor designed to block TGF-? activation within the tumor environment. This drug is presently in a Phase 1 open-label trial, which is evaluating its efficacy both as a standalone treatment and in combination with pembrolizumab for patients with solid tumors that have resisted immune checkpoint inhibitors.
Recent interim results from this ongoing trial have been promising, showing that PLN-101095 appears to be well tolerated, achieving confirmed partial responses in up to 50% of patients at the highest tested dose across various tumor types. The study is actively recruiting participants for its fifth planned dose cohort.
Innovative Drug Discovery Platform
Pliant’s innovative drug discovery platform is noteworthy, comprising a proprietary library of over 15,000 integrin-binding molecules alongside a sophisticated screening assay system. This platform showcases the company's commitment to exploring the utilization of integrin receptor-binding molecules for delivering drug payloads to specific tissues, potentially revolutionizing treatment across multiple disease conditions.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is at the forefront of biopharmaceutical innovation, focusing on the discovery and development of integrin-based therapeutics. Their ongoing work includes the Phase 1 study of PLN-101095, which presents a dual-selective mechanism targeting ?v?8 and ?v?1 integrins for solid tumor treatment. Additionally, they have received regulatory approval to conduct a Phase 1 study of PLN-101325, a monoclonal antibody designed to target muscular dystrophies.
As Pliant continues to push the boundaries of therapeutic development, they are also engaged in early-stage research aimed at enhancing drug delivery mechanisms, which play a crucial role in their overarching goal of developing effective therapies for complex diseases.
Frequently Asked Questions
What led to the discontinuation of BEACON-IPF?
The decision was based on recommendations from the Data Safety Monitoring Board, which identified safety risks associated with adverse events in patients.
What are the next steps for Pliant Therapeutics?
Pliant will focus on its ongoing oncology programs, particularly the PLN-101095 trial, while analyzing broader applications of its drug discovery platform.
What is PLN-101095?
PLN-101095 is a dual-selective inhibitor targeting integrins ?v?8 and ?v?1, being evaluated for its effectiveness in treating solid tumors resistant to other therapies.
How does Pliant’s drug discovery platform work?
The platform integrates a vast library of integrin-binding molecules with advanced screening assays to enhance drug delivery and efficacy across various disease areas.
How has patient safety influenced Pliant’s decisions?
Patient safety is paramount, guiding the company’s strategies and decisions in trial designs and the development of treatment protocols.
